ProVascTec

Executive Summary

ProVascTec is a preclinical-stage Irish cell therapy company developing an off-the-shelf stem cell treatment for critical limb ischemia (CLI) in below-the-knee peripheral artery disease. The therapy leverages paracrine signaling to stimulate de novo vascular network formation, creating a natural bypass around arterial occlusions. A proprietary percutaneous delivery device is designed to precisely administer the stem cells. CLI represents a significant unmet medical need with high amputation rates and limited treatment options. ProVascTec's approach aims to address the limitations of current revascularization therapies by providing a minimally invasive, off-the-shelf solution that could be broadly accessible. The company is currently advancing its lead candidate toward clinical development, with preclinical studies supporting its safety and efficacy profile.

Upcoming Catalysts (preview)

• Q2 2027IND/CTA submission for first-in-human trial60% success
• Q4 2026Publication of key preclinical data in peer-reviewed journal70% success
• TBDStrategic partnership or licensing deal for manufacturing or commercialization40% success